Therefore, the PERK/eIF2α/ATF4 pathway is often considered to play a key role in tumor progression and the development of cancer therapies (Chen et al., 2013; Cheng and Dong, 2018; Li et al., 2019). This evidence concerns the gene ATF4 and neoplasm.